REDEFINE 2 studied the cagrilintide–semaglutide combination in a different population from REDEFINE 1. A difference between trial averages is not automatically a randomized comparison between those populations. Primary trial
Study findings
The 68-week phase 3a trial randomized 1,206 adults with type 2 diabetes and qualifying BMI to the combination or placebo, alongside lifestyle intervention. The treatment-policy estimate of weight change was −13.7% with the combination and −3.4% with placebo. Weight-response and glycemic measures also favored the combination. Gastrointestinal adverse events were more frequent. Novo Nordisk funded the trial; registration is NCT05394519. Primary trial
Our appraisal: avoid an uncontrolled comparison of controlled trials
Two randomized trials can each support their own comparisons without providing a randomized comparison against each other. Populations, background care, eligibility, baseline values, and analysis methods may differ.
For an invented example, one trial could report a ten-unit change and another a fifteen-unit change. The five-unit difference between those summaries is not automatically the causal effect of the characteristic that differs between their participants. A valid effect-modification question needs an appropriate analysis.
Within this trial, weight change, reaching a weight threshold, and reaching an HbA1c threshold remain separate endpoints. Our full-paper review would inspect their hierarchy, missing-data handling, rescue treatment, subgroup membership, and safety denominators.
Frequently asked questions
Did this trial include people with type 2 diabetes?
Yes.
Was cagrilintide alone the active intervention?
No. The trial evaluated the combination with semaglutide.
Can its average be directly ranked against another trial's average?
Not as a randomized head-to-head comparison.
Are HbA1c targets identical to weight-loss targets?
No. They measure different outcomes.
Does a group response rate identify an individual's result?
No. It is not a personal forecast.
Is the page a treatment recommendation?
No. It is a historical study appraisal.
What remains before release?
Full report, statistical plan, participant flow, registry, safety, and publication-history review.